LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Redhill Biopharma Ltd.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERRDHL
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / RDHL COVERAGE

What’s moving Redhill Biopharma Ltd. now

Current reporting with the operating signal separated from the noise.

01
Share Price and Research

Redhill Biopharma Ltd (NASDAQ: RDHL)

The story matters when it changes Redhill Biopharma Ltd.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

The story matters when it changes Redhill Biopharma Ltd.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
RedHill Biopharma Ltd.: RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak

RedHill Biopharma Ltd.: RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak

The story matters when it changes Redhill Biopharma Ltd.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Earnings Call Transcript

RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q1 2022 Results

The story matters when it changes Redhill Biopharma Ltd.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Analysts Have Been Trimming Their RedHill Biopharma Ltd. (NASDAQ:RDHL) Price Target After Its Latest Report

Analysts Have Been Trimming Their RedHill Biopharma Ltd. (NASDAQ:RDHL) Price Target After Its Latest Report

The story matters when it changes Redhill Biopharma Ltd.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
06
When Can We Expect A Profit From RedHill Biopharma Ltd. (NASDAQ:RDHL)?

When Can We Expect A Profit From RedHill Biopharma Ltd. (NASDAQ:RDHL)?

Investors are testing whether Redhill Biopharma Ltd.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest RDHL filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

6-KOfficial SEC filingFiled 2026-07-28 · Period 2026-07-28SEC ↗6-KOfficial SEC filingFiled 2026-07-01 · Period 2026-07-01SEC ↗424B3Official SEC filingFiled 2026-07-14SEC ↗EFFECTOfficial SEC filingFiled 2026-07-13SEC ↗4Official SEC filingFiled 2026-07-13 · Period 2026-07-10SEC ↗F-3Official SEC filingFiled 2026-07-02SEC ↗6-KOfficial SEC filingFiled 2026-06-29 · Period 2026-06-29SEC ↗424B5Official SEC filingFiled 2026-06-29SEC ↗
EARNINGS / QUARTERLY TRACKER

Redhill Biopharma Ltd., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.